Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WSK-V102 recombinant COVID-19 vaccine sequential booster study
ChiCTR2200066820Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant COVID-19 variant vaccine in coronavirus disease 2019 (COVID-19), sponsored by West China Hospital of Sichuan University. Primary endpoints: Incidence of adverse reactions within 0–7 days after booster vaccination, Incidence of adverse reactions within 0–30 days after booster vaccination and 1 more. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
recombinant COVID-19 variant vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200066820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066820.